

Title (en)  
COMPOUND FOR TREATMENT OF CANCER

Title (de)  
VERBINDUNG ZUR BEHANDLUNG VON KREBS

Title (fr)  
COMPOSÉ POUR LE TRAITEMENT DU CANCER

Publication  
**EP 2959900 A1 20151230 (EN)**

Application  
**EP 15168526 A 20090616**

Priority  
• US 6187508 P 20080616  
• EP 09835407 A 20090616

Abstract (en)  
A compound, wherein the compound is (2-(1 H -indol-3-yl)imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone. A pharmaceutical composition comprising the compound is (2-(1 H -indol-3-yl)imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone and a pharmaceutically acceptable carrier. The compound (2-(1 H -indol-3-yl)imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone for use in treating prostate cancer, breast cancer, ovarian cancer, skin cancer, lung cancer, colon cancer, leukemia, renal cancer or CNS cancer, or a combination thereof.

IPC 8 full level  
**A61K 31/4178** (2006.01); **A61P 35/00** (2006.01); **C07D 403/04** (2006.01)

CPC (source: CN EP KR US)  
**A61K 31/4164** (2013.01 - KR); **A61K 31/4178** (2013.01 - EP US); **A61K 31/421** (2013.01 - EP KR US); **A61K 31/426** (2013.01 - EP KR US); **A61K 45/06** (2013.01 - US); **A61P 35/00** (2018.01 - EP); **A61P 35/02** (2018.01 - EP); **A61P 43/00** (2018.01 - EP); **C07D 233/02** (2013.01 - EP US); **C07D 233/22** (2013.01 - EP KR US); **C07D 233/54** (2013.01 - EP US); **C07D 263/06** (2013.01 - EP US); **C07D 263/14** (2013.01 - EP US); **C07D 263/32** (2013.01 - EP US); **C07D 263/34** (2013.01 - KR); **C07D 277/04** (2013.01 - EP US); **C07D 277/06** (2013.01 - KR); **C07D 277/24** (2013.01 - EP US); **C07D 277/28** (2013.01 - EP US); **C07D 277/56** (2013.01 - EP US); **C07D 401/04** (2013.01 - EP US); **C07D 401/06** (2013.01 - EP US); **C07D 403/04** (2013.01 - CN EP KR US); **C07D 413/04** (2013.01 - EP US); **C07D 413/06** (2013.01 - EP US); **C07D 417/04** (2013.01 - EP US); **C07D 417/06** (2013.01 - EP US)

Citation (applicant)  
• US 7307093 B2 20071211 - MILLER DUANE D [US], et al  
• US 2007155807 A1 20070705 - MILLER DUANE D [US], et al  
• "Cancer Facts & Figures", 2008, AMERICAN CANCER SOCIETY  
• LI ET AL.: "Synthesis and Antiproliferative Activity of Thiazolidine Analogs for Melanoma", BIOORG. MED. CHEM. LETT., vol. 17, 2007, pages 4113 - 7, XP022144655, DOI: doi:10.1016/j.bmcl.2007.05.059  
• LI ET AL.: "Structure-Activity Relationship Studies of Arylthiazolidine Amides as Selective Cytotoxic Agents for Melanoma", ANTICANCER RES., vol. 27, 2007, pages 883 - 888  
• LU ET AL.: "Synthesis and Biological Evaluation of 2-Arylthiazolidine-4-Carboxylic Acid Amides for Melanoma and Prostate Cancer", ABSTRACTS OF PAPERS, 234TH ACS NATIONAL MEETING, BOSTON, MA, UNITED STATES, 19 August 2007 (2007-08-19)  
• GUDUDURU ET AL.: "SAR Studies of 2-Arylthiazolidine-4-Carboxylic Acid Amides: A Novel Class of Cytotoxic Agents for Prostate Cancer", BIOORG. MED. CHEM. LETT., vol. 15, 2005, pages 4010 - 4013, XP025314062, DOI: doi:10.1016/j.bmcl.2005.06.032  
• GUDUDURU ET AL.: "Discovery of 2-Arylthiazolidine-4-Carboxylic Acid Amides as a New Class of Cytotoxic Agents for Prostate Cancer", J. MED. CHEM., vol. 48, 2005, pages 2584 - 2588  
• RAJ ET AL.: "Guanosine Phosphate Binding Protein Coupled Receptors in Prostate Cancer: A Review", I UROL., vol. 167, 2002, pages 1458 - 1463, XP005539922, DOI: doi:10.1016/S0022-5347(05)65345-1  
• KUE ET AL.: "Essential Role for G Proteins in Prostate Cancer Cell Growth and Signaling", J. UROL., vol. 164, 2000, pages 2162 - 7, XP005554243, DOI: doi:10.1016/S0022-5347(05)66990-X  
• GUO ET AL.: "Expression and Function of Lysophosphatidic Acid LPA1 Receptor in Prostate Cancer Cells", ENDOCRINOLOGY, vol. 147, 2006, pages 4883 - 4892  
• QI ET AL.: "Lysophosphatidic Acid Stimulates Phospholipase D Activity and Cell Proliferation in PC-3 Human Prostate Cancer Cells", J. CELL. PHYSIOL., vol. 174, 1998, pages 261 - 272, XP002076182, DOI: doi:10.1002/(SICI)1097-4652(199802)174:2<261::AID-JCP13>3.0.CO;2-F  
• HIGUCHI; STELLA: "Pro-drugs as Novel Delivery Systems", vol. 14, ACS SYMPOSIUM SERIES  
• E B ROCHE.: "Bioreversible Carriers in Drug Design", 1987, PERGAMON PRESS  
• BERGERON ET AL.: "Evaluation of Desferriethiocin and its Synthetic Analogs as Orally Effective Iron Chelators", J. MED. CHEM., vol. 34, 1991, pages 2072 - 8, XP002182655, DOI: doi:10.1021/jm00111a023  
• BERGERON ET AL.: "Desazadesmethyl-desferriethiocin Analogues as Orally Effective Iron Chelators", J. MED. CHEM., vol. 42, 1999, pages 95 - 108, XP001174119, DOI: doi:10.1021/jm980340j  
• ZAMRI ET AL.: "An Improved Stereocontrolled Synthesis of Pyochelin, Siderophore of Pseudomonas aeruginosa and Burkholderia cepacia", TETRAHEDRON, vol. 56, 2000, pages 249 - 256, XP002252917, DOI: doi:10.1016/S0040-4020(99)00946-1  
• NAHM ET AL.: "N-Methoxy-N-methylamides as Effective Acylating Agents", TETRAHEDRON LETT., vol. 22, 1981, pages 3815 - 18, XP055320656, DOI: doi:10.1016/S0040-4039(01)91316-4  
• MEYER ET AL., TETRAHEDRON: ASYMMETRY, vol. 14, 2003, pages 2229 - 2238  
• ANDERSON ET AL., J. MED. CHEM., vol. 32, no. 1, 1989, pages 119 - 127  
• JESBERGER ET AL., SYNTHESIS, 2003, pages 1929 - 1958  
• GREEN ET AL.: "Protective Groups in Organic Synthesis, 2nd Ed.", 1991, WILEY-INTERSCIENCE  
• WILLIAMS ET AL.: "Studies of Mild Dehydrogenations in Heterocyclic Systems", TETRAHEDRON LETT., vol. 38, 1997, pages 331 - 334, XP004015000, DOI: doi:10.1016/S0040-4039(96)02344-1  
• G.M. SHELDRICK, SHELXL-97, 1997  
• RUBINSTEIN ET AL.: "Comparison of in vitro Anticancer Drug-screening Data Generated with a Tetrazolium Assay Versus a Protein Assay Against a Diverse Panel of Human Tumor Cell Lines", J. NATL. CANCER INST., vol. 82, 1990, pages 1113 - 1118  
• DOTHAGER ET AL.: "Synthesis and Identification of Small Molecules that Potently Induce Apoptosis in Melanoma Cells Through G1 Cell Cycle Arrest", J. AM. CHEM. SOC., vol. 127, 2005, pages 8686 - 8696, XP055014477, DOI: doi:10.1021/ja042913p  
• MARGOLIS ET AL.: "Addition of Colchicine--Tubulin Complex to Microtubule Ends: The Mechanism of Substoichiometric Colchicine Poisoning", PROC. NAT'L ACAD. SCI. USA, vol. 74, 1977, pages 3466 - 70  
• RIEDRICH ET AL., ANGEWANDTE CHEMIE, INTERNATIONAL EDITION, vol. 46, no. 15, 2007, pages 2701 - 2703

- BERGERON ET AL., J. MED. CHEM., vol. 48, 2005, pages 821 - 831
- HSU ET AL., J. MED. CHEM., vol. 23, no. 11, 1980, pages 1232 - 1235

Citation (search report)

- [A] WO 2008038955 A1 20080403 - CHONG KUN DANG PHARM CORP [KR], et al
- [A] WO 2005086902 A2 20050922 - SCION PHARMACEUTICALS INC [US], et al
- [A] TUCKER, J. A. ET AL: "Structure-activity relationships of acyloxyamidines cytomagalovirus DNA polymerase inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 8, no. 3, 2000, pages 601 - 615, XP002668129

Cited by

US11465987B2; US11084811B2

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

DOCDB simple family (publication)

**US 2009326020 A1 20091231; US 8592465 B2 20131126;** AU 2009330686 A1 20100701; AU 2009330686 B2 20140703; CA 2728118 A1 20100701; CA 2728118 C 20180116; CA 2962524 A1 20100701; CA 2962524 C 20200714; CN 102137592 A 20110727; CN 102137592 B 20150128; CN 104610230 A 20150513; CY 1119217 T1 20180214; CY 1121724 T1 20200731; DK 2303021 T3 20190408; DK 2959900 T3 20170626; DK 3289876 T3 20221010; EP 2303021 A2 20110406; EP 2303021 A4 20120314; EP 2303021 B1 20181219; EP 2959900 A1 20151230; EP 2959900 B1 20170308; EP 3289876 A1 20180307; EP 3289876 B1 20220720; ES 2629927 T3 20170816; ES 2715926 T3 20190607; ES 2927660 T3 20221110; HR P20221086 T1 20221125; HU E034598 T2 20180228; HU E043569 T2 20190828; HU E060249 T2 20230228; IL 209995 A0 20110228; IL 209995 A 20140528; IL 229878 A0 20140130; IL 229878 A 20150430; JP 2011524422 A 20110901; JP 2012162541 A 20120830; JP 5507552 B2 20140528; KR 102025213 B1 20190925; KR 20110022672 A 20110307; KR 20160079934 A 20160706; KR 20170029031 A 20170314; KR 20170128623 A 20171122; LT 2303021 T 20190625; LT 2959900 T 20170925; LT 3289876 T 20221110; MX 2010014066 A 20110601; PL 2303021 T3 20191031; PL 2959900 T3 20171130; PL 2959900 T4 20171130; PL 3289876 T3 20221121; PT 2303021 T 20190401; PT 2959900 T 20170622; PT 3289876 T 20221028; RU 2010154172 A 20120727; RU 2514427 C2 20140427; SI 3289876 T1 20230131; TR 201903981 T4 20190422; UA 105005 C2 20140410; US 10865196 B2 20201215; US 2019092755 A1 20190328; WO 2010074776 A2 20100701; WO 2010074776 A3 20100819

DOCDB simple family (application)

**US 48588109 A 20090616;** AU 2009330686 A 20090616; CA 2728118 A 20090616; CA 2962524 A 20090616; CN 200980131946 A 20090616; CN 201410828197 A 20090616; CY 171100601 T 20170608; CY 191100320 T 20190318; DK 09835407 T 20090616; DK 15168526 T 20090616; DK 17196904 T 20090616; EP 09835407 A 20090616; EP 15168526 A 20090616; EP 17196904 A 20090616; ES 09835407 T 20090616; ES 15168526 T 20090616; ES 17196904 T 20090616; HR P20221086 T 20090616; HU E09835407 A 20090616; HU E15168526 A 20090616; HU E17196904 A 20090616; IL 20999510 A 20101214; IL 22987813 A 20131209; JP 2011514764 A 20090616; JP 2012072925 A 20120328; KR 20117001037 A 20090616; KR 20167017425 A 20090616; KR 20177006276 A 20090616; KR 20177032778 A 20090616; LT 09835407 T 20090616; LT 15168526 T 20090616; LT 17196904 T 20090616; MX 2010014066 A 20090616; PL 09835407 T 20090616; PL 15168526 T 20090616; PL 17196904 T 20090616; PT 09835407 T 20090616; PT 15168526 T 20090616; PT 17196904 T 20090616; RU 2010154172 A 20090616; SI 200932173 T 20090616; TR 201903981 T 20090616; UA A201015111 A 20090616; US 2009047572 W 20090616; US 201815872199 A 20180116